ImpediMed Limited - Special Call Transcript
Thank you for standing by, and welcome to the ImpediMed Investor Update Meta-Analysis Publication. (Operator Instructions).
I would now like to hand the conference over to Mr. Richard Carreon, Managing Director and CEO. Please go ahead.
Thank you, Amanda. Good morning, and thank you for joining us this morning. This call is to discuss the meta-analysis that was published this weekend in Breast Cancer Research and Treatment journal.
With me today are Cathy Kingsford, our Senior VP of Clinical and Regulatory; and the lead author of the meta-analysis, Dr. Chirag Shah.
Before I turn the call over to Dr. Shah, let me provide you a summary of his impressive background. Dr. Shah is the associate staff in the Department of Radiation Oncology and Director of Clinical Research in the Department of Radiation Oncology, the world-famous Cleveland Clinic. Dr. Shah received his Bachelor's degree from Youngstown State University and his medical degree from Northeast
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |